Globus Medical, Inc. (GMED) Down 6.1% — Time to Reverse Course?
Globus Medical, Inc. (GMED) stumbled sharply in Tuesday's session, dropping $4.83 to close at $74.92 on the NYSE. The decline is a meaningful setback for a stock that had already been navigating a complicated year — GMED reached its 52-week high of $101.40 on January 8, 2026, and Tuesday's close leaves it sitting roughly 26.1% below that peak, a gap that underscores how much ground has been lost since the early-year momentum peaked.
Volume came in at approximately 548,000 shares against the 90-day average of about 1.52 million — well below typical turnover for this name. That light trading on a down day suggests the selling was concentrated rather than panic-driven, though it also reflects a meaningful absence of buyers willing to step in and absorb the news at current levels.
Why Globus Medical, Inc. Price is Moving Lower
The catalyst is a leadership shock compounded by an underwhelming fundamental update. CEO Dan Scavilla unexpectedly announced his resignation to join Dentsply Sirona, triggering approximately a 6% intraday drop as investors processed what the departure means for a company in the middle of a complex integration cycle. COO and CFO Keith Pfeil is being elevated to the CEO role — a promotion that may ultimately prove sound, but which introduces real uncertainty at a moment when Globus Medical is simultaneously integrating Nevro and managing multiple growth initiatives that demand strategic continuity and sharp execution.
The business backdrop made the leadership news land harder than it otherwise might have. Preliminary Q2 2026 figures showed core business revenue — excluding Nevro — at roughly $650.8 million, which fell short of investor expectations. Including Nevro, total Q2 revenue is projected at approximately $745.3 million against a consensus estimate of about $738.9 million, a modest beat on the headline. But management's decision not to raise full-year guidance despite having a full quarter of Nevro contribution baked in was read as a warning sign, suggesting the underlying business may be running softer than the combined-entity numbers imply. When a company integrates a sizable acquisition and still doesn't find room to lift its outlook, the market tends to draw cautious conclusions.
Adding to the pressure, Stifel Nicolaus set a $80 price target on GMED earlier this month — a level the stock has now slipped below — framing modest expectations after shares had rallied roughly 62.5% over six months to around $87. That run-up left the stock priced for execution, making it especially vulnerable to any leadership or guidance disappointment. With shares now trading at $74.92, Stifel's $80 target offers only a marginal implied upside and is unlikely to function as a meaningful floor given the new uncertainties.
What is the Globus Medical, Inc. Rating - Should I Sell?
Weiss Ratings assigns GMED a C rating. Current recommendation is Hold.
The sub-index profile reflects a genuine split between operational strength and the risks investors are now weighing more carefully. Revenue growth of 27.04% earns the Excellent Growth Index — a figure that reflects real commercial momentum, particularly as the Nevro integration begins to contribute meaningfully to the top line. The Excellent Solvency Index points to a balance sheet with the capacity to absorb near-term integration costs without stress. A profit margin of 18.92% and ROE of 13.30% together earn the Good Efficiency Index, reasonable metrics for a medical device company managing the friction of a large merger, though neither is exceptional enough to drive the rating higher on its own.
Where the picture softens is in the Fair Total Return Index and Fair Volatility Index. The Fair Total Return Index signals that GMED has not consistently delivered the kind of risk-adjusted performance that earns stronger conviction, and today's 26% retreat from the 52-week high reinforces that point. The Fair Volatility Index is worth taking seriously given the leadership transition — Pfeil stepping into the CEO seat adds a layer of uncertainty that the market is already pricing in, and it raises the likelihood of continued price swings as investors wait for evidence that strategy and execution remain on track.
A forward P/E of 18.59 against EPS of $4.29 is not a stretched valuation in isolation, but the multiple reflects a guidance reset that management has not seen fit to upgrade. Within the Health Care sector, Globus Medical sits alongside UnitedHealth Group Incorporated (UNH, C), Intuitive Surgical, Inc. (ISRG, C), and Stryker Corporation (SYK, C) — peers facing their own headwinds, but without the fresh leadership disruption that Globus Medical is now absorbing. Abbott Laboratories (ABT, C-) rates below GMED, which offers some relative perspective, though it is cold comfort on a day like Tuesday.
About Globus Medical, Inc.
Globus Medical, Inc. (GMED) is a Health Care company focused primarily on the design, development, and commercialization of musculoskeletal solutions. The company's core business is spine — a category in which it competes across surgical implants, enabling technologies, and minimally invasive techniques intended to reduce surgical complexity and improve patient outcomes. Its product portfolio spans spinal fusion, motion preservation, and deformity correction, supported by navigation and robotic-assisted surgical platforms that have become increasingly central to its competitive positioning in the operating room.
The acquisition of Nevro significantly expanded Globus Medical's addressable market by adding a leading neuromodulation franchise — specifically spinal cord stimulation for the management of chronic pain. That move extended the company's reach from the surgical suite into a therapy-driven category where long-term device implants generate a recurring clinical relationship with both physicians and patients. The combination creates a broader musculoskeletal platform that spans acute surgical intervention and chronic disease management, a strategic pairing that management has argued enhances commercial cross-sell opportunities across its shared hospital and ambulatory surgery center customer base.
Globus Medical's competitive advantages include a substantial intellectual property portfolio, a dedicated direct sales force with deep surgeon relationships, and proprietary manufacturing capabilities that support both product quality and margin management. Its investment in robotics and imaging-guided surgery reflects a longer-term bet that procedural technology will increasingly serve as a differentiator in winning implant business — a dynamic playing out across the spine and orthopedics industry more broadly.
Investor Outlook
Globus Medical, Inc. (GMED) carries a Weiss Rating of C (Hold), and Tuesday's session is a reminder that the stock faces real near-term headwinds as investors recalibrate around a new CEO and a guidance profile that has not expanded alongside the Nevro contribution. The most important factors to monitor in the coming weeks are Keith Pfeil's first communications as CEO, any updated strategic framing around integration milestones, and whether Q2 results confirm or challenge the softer core revenue trend signaled in preliminary figures. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--